Literature DB >> 8018569

The effect of prophylactic trimethoprim on aerobic urinary tract infection during pelvic radiotherapy and the incidence of infections due to fastidious or anaerobic organisms.

E M Bessell1, M Granville-White.   

Abstract

A total of 210 patients receiving pelvic radiotherapy were prescribed trimethoprim 200 mg p.o. daily for the duration of radiotherapy. It was prescribed after two mid-stream urine specimens were obtained. Two patients refused to take trimethoprim. The incidence of urinary tract infection prior to starting radiotherapy and trimethoprim was 24% (50 patients). Of these 50 initial infections, eight (16%) were resistant to trimethoprim, necessitating a change to an antibiotic to which the organism was sensitive. Persistent infection occurred in 21 of these 50 patients; 14 (67%) of these infections were resistant to trimethoprim. Of the 160 patients with no initial infection, 25 subsequently developed a urinary tract infection, in spite of prophylactic trimethoprim. Seven of these 25 infections (28%) were resistant to trimethoprim. Prophylactic trimethoprim is not worthwhile for preventing urinary tract infection during pelvic radiotherapy. Eight patients (4%) developed a rash while on trimethoprim, necessitating stopping the drug. Fastidious or anaerobic organisms were isolated in only 15 patients prior to radiotherapy and in seven patients during radiotherapy. Twenty of these 22 patients were female. The organism most commonly isolated was Streptococcus sp. The bacteriuria occurring with these organisms may have resulted from contamination from the vagina.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018569     DOI: 10.1016/s0936-6555(05)80114-1

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

1.  The risk factors of urinary tract infection after transurethral resection of bladder tumors.

Authors:  Yuki Kohada; Akihiro Goriki; Kazuma Yukihiro; Shinya Ohara; Mitsuru Kajiwara
Journal:  World J Urol       Date:  2019-03-26       Impact factor: 4.226

2.  Enteric-coated, highly standardized cranberry extract reduces risk of UTIs and urinary symptoms during radiotherapy for prostate carcinoma.

Authors:  Alberto Bonetta; Francesco Di Pierro
Journal:  Cancer Manag Res       Date:  2012-08-24       Impact factor: 3.989

3.  Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma.

Authors:  Alberto Bonetta; Giandomenico Roviello; Daniele Generali; Laura Zanotti; Maria Rosa Cappelletti; Chiara Pacifico; Francesco Di Pierro
Journal:  Res Rep Urol       Date:  2017-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.